• / Free eNewsletters & Magazine
  • / My Account
Home>Onxeo to host a Conference Call today to comment on the main findings from ReLive Phase III Study of Livatag®

Onxeo to host a Conference Call today to comment on the main findings from ReLive Phase III Study of Livatag®

Onxeo to host a Conference Call today to comment on the main findings from ReLive Phase III Study of Livatag®

09/18/2017

Onxeo to host a Conference Call today to comment on the main findings from ReLive Phase III Study of Livatag®

Regulatory News:

Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO) (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or the “Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, will host a conference call today for its shareholders at 3.00 pm CEST to comment on the main data from the ReLive Phase III Study of Livatag®.

This presentation will set out the main study data presented at the 11th Annual Conference of the International Liver Cancer Association in Seoul, South Korea (ILCA – 15-17 September 2017).

Conference call on September 18, 2017 at 3.00 pm CEST

Dial: +33 (0)1 72 00 15 10

Participant code: 92479704#

The call will be held in French

©2017 Morningstar Advisor. All right reserved.